Optometric education's past helps predict the future

Article

Optometric continuing education is the barometer of our history and our future.

Optometric continuing education (CE) is the barometer of our history and our future.

Tracing the origins

In the early 1990s, LASIK co-management classes were guaranteed to fill the classrooms, yet today those classes hardly draw a soul.

Glaucoma diagnosis classes became particularly popular when optometric pioneers, such as Murray Fingeret (often referred to as the "Godfather of Glaucoma"), began giving visual field interpretation courses. Later, glaucoma co-management and treatment courses began appearing and remain popular today.

Niche meetings, such as the annual meeting of the American Academy of Optometry (AAO), could be counted on to emphasize new research in vision and continue today to be the place to go to learn about these new developments, even though they may lack in daily clinical application. SECO remains a popular "clubby" home to southeastern practitioners, and emphasizes practical clinical training for primary care optometrists like myself. I never miss it.

Recent Videos
Rachelle Lin, OD, MS, FAAO, details her presentation on inherited retinal diseases at CRU 2025.
Setting the stage in LA: Neda Shamie, MD, on the 19th annual Controversies in Modern Eye Care meeting
Jennifer Li, MD, details a talk she gave alongside Melissa Barnett, OD, FAAO, FSLS, FBCLA, at CRU 2025 in Napa, California.
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
Dr Paul Karpecki discusses atropine formulation from Sydnexis following NDA acceptance by FDA
Ali Tafreshi sits down with Optometry Times to discuss Topcon's "Healthcare from the Eye" initiative.
© 2025 MJH Life Sciences

All rights reserved.